SV2A Ligands Market
Number of pages: 100 | Report Format: PDF | Published date: April 17, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.5% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drugs, Types of Seizures, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global SV2A market is expected to register a revenue CAGR of 3.5%.
SV2A Ligands Market Fundamentals
Synaptic vesicle protein 2A (SV2A) ligands are medications used to treat various forms of seizures. The brain-binding location for seizure medicines has been identified as SV2A. The significant attraction of SV2A ligands to SV2A protein in the brain may contribute to its antiepileptic activity. This protein is found in nearly all nerve cells. SV2A ligands bind to the SV2A protein to change brain chemical release and assist electrical impulse inhibition. SV2 proteins are 12-transmembrane glycoproteins found on brain cell synaptic vesicles and are members of the vast and widely dispersed major facilitator superfamily (MFS). SV2 is divided into three isoforms: SV2A, SV2B, and SV2C. Only SV2A is expressed in virtually all presynaptic vesicles. This suggests that it might be used as a biomarker for synaptic density with other proteins expressed in the presynaptic proteome and synaptic vesicles. The anti-epileptic drugs levetiracetam and brivaracetam target SV2A.
The development of levetiracetam's anti-seizure effectiveness is an example of a successful collaboration between academics and industry. Levetiracetam, formerly known as UCB L059, is the S-enantiomer of piracetam's ethyl analog, a nootropic medicine used to treat cortical myoclonus, cerebrovascular insufficiencies, and age-related cognitive decline. Levetiracetam was developed in 1977 at UCB Pharma in Belgium during studies to find a second-generation nootropic medication to replace piracetam, but it failed to show substantial therapeutic efficacy in patients with cognitive impairment.
Brivaracetam (BRV) is an LEV (levetiracetam) analog engineered to have a greater affinity and selectivity for SV2A, a protein involved in synaptic vesicle exocytosis and neurotransmitter release. In a recent phase 3 study of people with uncontrolled partial-onset (focal) seizures, BRV demonstrated effectiveness and tolerability. BRV has a linear and predictable pharmacokinetic profile with little inter-individual variability, quick and full absorption upon oral administration, low plasma protein binding, and an elimination half-life of 7 to 8 hours. Furthermore, BRV was discovered to have negligible drug-drug interactions. The current preclinical study was conducted to compare the brain pharmacokinetics of BRV and its start of seizure protection to LEV.
SV2A Ligands Market Dynamics
Epilepsy is a common neurological illness that affects approximately 70 million people globally. At the same time, there are several types of epileptic seizures, such as nonconvulsive, convulsive, focal, and generalized seizures. Epilepsy is not a single disease or syndrome; rather, it is a wide range of situations. The major treatment for this illness, which is characterized by recurrent seizures, is antiepileptic drug (AED) therapy. Around two-thirds of people with epilepsy can manage their seizures if it is properly detected and treated.
The increasing number of drugs approved by regulatory agencies is expected to promote the expansion of the global market. Rising epilepsy prevalence is expected to fuel market development in regions such as the United States over the forecast period. For instance, according to the World Health Organization, the estimated proportion of the general population with active epilepsy is between 4 and 10 per 1000 persons. Each year, an estimated 5 million people globally are diagnosed with epilepsy. Epilepsy is projected to affect 49 persons out of every 100,000 in high-income nations annually. This ratio can reach 139 per 100,000 people in low- and middle-income nations. This is most likely owing to the increased risk of endemic diseases such as malaria or neurocysticercosis, the increased frequency of road traffic accidents, birth-related injuries, disparities in medical infrastructure, the availability of preventative health initiatives, and accessible care. Nearly 80% of epileptics live in low- and middle-income nations. According to the Child Neurology Foundation, around 50 to 60 percent of children with seizures will eventually grow out of them and never have seizures as adults. Furthermore, epilepsy is most usually diagnosed before age 20 or after age 65, and the rate of new cases rises after age 55 when people are more likely to suffer from strokes, tumors, and Alzheimer's disease.
SV2A Ligands Market Ecosystem
The global SV2A ligands market has been analyzed from four perspectives: drugs, types of seizures, distribution channel, and region.
SV2A Ligands Market by Drugs
[45645]
Based on drugs, the global SV2A ligands market is segmented into brivaracetam, levetiracetam, and others.
The brivaracetam segment showed lucrative revenue growth during the forecast period. Brivaracetam (BRV) is a highly selective and reversible SV2A ligand with a 15- to 30-fold greater affinity in the rat or human brain than levetiracetam. BRV has been demonstrated in studies to be an effective and well-tolerated supplementary therapy in patients with RFS. However, it is still being determined which has greater effectiveness or tolerability for treating RFS patients. Many randomized, double-blind, placebo-controlled trials for patients with RFS have examined the effectiveness and tolerance of LEV and BRV.
Additionally, brivaracetam's anti-myoclonic activity was already maximum at that dosage, but it increased dose-dependently with levetiracetam, indicating that brivaracetam is a more powerful drug. Both substances had a similar start and duration of anti-myoclonic action. This data shows that brivaracetam has stronger anti-seizure and anti-myoclonic action than levetiracetam; the aforementioned factors drive the segmental revenue growth.
SV2A Ligands Market by Types of Seizures
Based on the types of seizures, the global SV2A ligands market is segmented into myoclonic seizures, partial onset seizures, and primary generalized tonic-clonic seizures.
The myoclonic seizures, partial onset seizures segment, showed significant revenue growth during the forecast period. Myoclonic-atonic epilepsy develops between 7 months and 6 years (peak age 2 to 4 years). Prior to the beginning of seizures, 85% of afflicted children have normal development; the remaining have mild psychomotor impairments, primarily impacting speech. The most likely onset times are before 6 months and beyond 6 years. The beginning of feverish and afebrile generalized tonic-colonic seizures precedes the onset of myoclonic-atonic seizures in two-thirds of individuals. The rising prevalence of myoclonic seizures is driving the market revenue. For instance, Epilepsy with Myoclonic-Atonic Seizures affects around 2% of all epileptic children. This equates to less than one in every 100,000 children born each year. One in every four children has their first seizure before their first birthday, and 94% occur before age five. Around 22% of MAE individuals suffer absence seizures, and up to 9% have myoclonic-atonic seizures in their first epileptic episode. However, approximately 60% to 80% of individuals achieve remission by medication or diet. With the first antiepileptic medicines (AED) provided, around 65% of children with newly diagnosed epilepsy attain prolonged seizure freedom.
SV2A Ligands Market by Distribution Channel
Based on the distribution channel, the global SV2A ligands market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
The hospital pharmacy segment is likely to dominate the SV2A ligand market. Patients with myoclonic-atonic seizures who have epilepsy rely on their medications to maintain their daily lives feeling normal. As hospitals have modern monitoring systems, the hospital chemist may recognize growing health concerns and prevent the progression of comorbidities through pharmacotherapeutic monitoring. In addition, the number of hospitals is growing, and these institutions are implementing appropriate reimbursement policies, which are significant drivers of hospital pharmacy development.
During the forecast period, retail pharmacies will gain the fastest revenue share. With greater product penetration in the market, the availability of seizure medications in retail pharmacies has accelerated the total market's sales rise. Furthermore, with the increasing global prevalence of epilepsy, the retail pharmacy sector is expected to increase profitably in terms of revenue share during the forecast period.
SV2A Ligands Market by Region
Based on region, the global SV2A ligands market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The North American region is expected to develop significantly during the forecast period, owing to the rising prevalence of epilepsy and market participants' strategic efforts, awareness campaigns, and product releases. Furthermore, the approval of medications for various aging groups supports market development. For example, in August 2021, UCB gained FDA clearance for an extended indication for BRIVIACT (brivaracetam) CV tablets, an oral solution and injectable to treat partial-onset seizures in kids as young as one-month-old. This is the first time BRIVIACT IV will be offered to pediatric patients when oral administration is impossible. It was among the earliest IV formulations approved to treat partial-onset seizures in children one month and older (nearly seven years).
During the forecast period, Europe is expected to grow significantly. The United Kingdom is the top revenue generator in the European market. Because this market is less mindful than others, it is likely to maintain its lead until the conclusion of the forecast period. Due to its greater population and the high number of epilepsy patients, Germany is Europe's second biggest anti-seizure medicine market, with France rounding out the top three in terms of revenue. Furthermore, the region's rising demand for innovative healthcare services drives market revenue.
SV2A Ligands Competitive Landscape
The market under evaluation is consolidated because of a few large market participants. As a result, the majority of important companies are focused on business growth to enhance their market revenue share. They also pursue specialized initiatives like new product development, mergers, and acquisitions.
The prominent market players operating in the global SV2A ligands market include,
SV2A Ligands Strategic Developments
Synaptic vesicle protein 2A (SV2A) ligands are medications used to treat various forms of seizures. The brain-binding location for seizure medicines has been identified as SV2A. The significant attraction of SV2A ligands to SV2A protein in the brain may contribute to its antiepileptic activity.
The rising prevalence of epilepsy and research & development initiatives by the government are prime driving factors.
The myoclonic seizures showed significant growth in the global SV2A ligands market.
The expected revenue CAGR of the global SV2A ligands market during the forecast period will be 3.5%.
Some prominent global SV2A ligands market players include UCB S.A., Abbott Laboratories, and GlaxoSmithKline PLC.
*Insights on financial performance are subject to the availability of information in the public domain